Future Science OA最新文献_第2页

Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-26 DOI: 10.1080/20565623.2025.2482487

Xiao-Song Chen, Feng Chen, Shu-Jia He, Yi-Yang Chen, Bang-Teng Chi, Wan-Ying Huang, Yue Wei, Chun-Yan Zhao, Chang Song, Rong-Quan He, Gang Chen, Jin-Liang Kong, Hui-Ping Lu

{"title":"Elevated expression of ANAPC1 in lung squamous cell carcinoma: clinical implications and mechanisms.","authors":"Xiao-Song Chen, Feng Chen, Shu-Jia He, Yi-Yang Chen, Bang-Teng Chi, Wan-Ying Huang, Yue Wei, Chun-Yan Zhao, Chang Song, Rong-Quan He, Gang Chen, Jin-Liang Kong, Hui-Ping Lu","doi":"10.1080/20565623.2025.2482487","DOIUrl":"10.1080/20565623.2025.2482487","url":null,"abstract":"Aim: To investigate the comprehensive expression levels and possible molecular mechanisms of Anaphase Promoting Complex Subunit 1 (ANAPC1) in lung squamous cell carcinoma (LUSC).Methods: Data from 2,031 samples were combined to evaluate ANAPC1 mRNA levels, and 118 samples were collected for immunohistochemical (IHC) analysis. High-expression co-expressed genes (HECEGs) associated with ANAPC1 were analyzed for signaling pathways. Clinical significance, immune computations, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) validation of ANAPC1's role in LUSC were assessed. Molecular docking evaluated binding affinity with potential therapeutics.Results: ANAPC1 mRNA was significantly upregulated in LUSC (SMD = 1.97, 95% CI [1.26-2.67]). Protein-level analysis confirmed this upregulation (p < 0.001). Most HECEGs associated with ANAPC1 were enriched in cell cycle pathways. Higher ANAPC1 expression correlated with poorer survival in LUSC patients (HR = 1.11, 95% CI: 1-1.49). ANAPC1 expression was higher in males and N1-stage vs. females and N0-stage; lower in grade I vs. II/III. Overexpression reduces immune cell infiltration and immunotherapy effectiveness, while knockdown inhibits cell proliferation. Drug sensitivity and docking analyses identified tenovin-1, carboxyatractyloside, and phycocyanobilin as potential antitumor agents targeting ANAPC1.Conclusion: The elevated expression of ANAPC1 might play a role in LUSC advancement and progression through its participation in cell growth-related pathways.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2482487"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioanalytical method validation to quantify ketorolac in human vitreous and aqueous via surrogate matrix of human plasma.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-19 DOI: 10.1080/20565623.2025.2476866

Prajita Pandey, Brianna A White, Colin Goswell, Neelanjan Bose, Sara Butterworth Connell, Nicolee Schulze, Jim Nevelos, Ana Najafi, Ramin Najafi, Ryan K Cheu

{"title":"Bioanalytical method validation to quantify ketorolac in human vitreous and aqueous via surrogate matrix of human plasma.","authors":"Prajita Pandey, Brianna A White, Colin Goswell, Neelanjan Bose, Sara Butterworth Connell, Nicolee Schulze, Jim Nevelos, Ana Najafi, Ramin Najafi, Ryan K Cheu","doi":"10.1080/20565623.2025.2476866","DOIUrl":"10.1080/20565623.2025.2476866","url":null,"abstract":"Purpose: Intracameral phenylephrine 1.0%/ketorolac 0.3% (OMIDRIA®) is used during cataract surgery to prevent intraoperative miosis and reduce postoperative pain. Although studied in beagles, no human data exist showing the duration ketorolac remains in the eye postoperatively. A clinical trial measuring ketorolac concentrations in aqueous/vitreous samples necessitated the development of a validation process for acquiring these measurements. Due to limited human aqueous/vitreous humor sample availability, a bioanalytical method was developed and validated to quantify ketorolac levels using human plasma as a surrogate matrix.Methods: The developed process involves extracting ketorolac and its internal standard (ketorolac-d5) from plasma as a surrogate for aqueous and vitreous humor using a protein precipitation sample preparation technique, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.Results: The validated method can be successfully applied for quantitation of ketorolac over a concentration range of 2.5 ng/mL to 5000 ng/mL. The method met the acceptance criteria with respect to selectivity, specificity, precision, accuracy, linearity, dilution integrity, and stability.Conclusions: The validated method can use plasma as a surrogate matrix for quantitation of ketorolac in aqueous and vitreous humor, thereby eliminating the need to procure human vitreous and aqueous samples for validation prior to initiation of a clinical trial.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2476866"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracellular vesicles in the pathogenesis and future diagnostics of oral squamous cell carcinoma.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/20565623.2025.2461940

Anđela Batur, Ruđer Novak, Grgur Salai, Stela Hrkač, Vesna Ćosić, Lovorka Grgurević

引用次数: 0

Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/20565623.2025.2459001

Xiaoyue Zhao, Min Luo, Qinjie Tian

{"title":"Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women.","authors":"Xiaoyue Zhao, Min Luo, Qinjie Tian","doi":"10.1080/20565623.2025.2459001","DOIUrl":"10.1080/20565623.2025.2459001","url":null,"abstract":"Objective: To investigate the therapeutic selection of abnormal uterine bleeding with ovulatory dysfunction (AUB-O) among Chinese women and analyze the impact of various factors.Methods: This was a cross-sectional study involving 3527 patients with AUB-O diagnosed by local doctor between 14 and 55 years old. Questionnaire compiled according to the Chinese AUB-O treatment guidelines was used to collect the demographic and therapeutic information.Results: The patients were divided into the juvenile group, the reproductive group, and the senior group. The results showed that irregular menstruation (37.6-46.3%), dysmenorrhea (29.9-44.4%), and heavy menstrual bleeding (16.7-32.2%) were the main symptoms in Chinese AUB-O patients. Most of the patients chose to seek help in the Department of General Gynecology (78.6-90.7%). Among the therapeutic options, combined oral contraceptives (COCs) met the treatment expectations with high acceptance among patients (36.6%-52.2%).Conclusion: This study underscores the crucial need to fortify the endocrine diagnostic proficiency of doctors within the Department of General Gynecology. Furthermore, it also indicates that implementing clinical medication education programs for patients could facilitate their correct selection of appropriate therapeutic strategies for AUB-O.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2459001"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of polyherbal synergy against diabetes: in-vitro analysis.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-21 DOI: 10.1080/20565623.2025.2468128

Sridevi N, Thirumal M

{"title":"Evaluation of polyherbal synergy against diabetes: in-vitro analysis.","authors":"Sridevi N, Thirumal M","doi":"10.1080/20565623.2025.2468128","DOIUrl":"10.1080/20565623.2025.2468128","url":null,"abstract":"Aims: To evaluate the anti-diabetic properties of a polyherbal formulation consisting of Curcuma longa, Emblica officinalis, and Trigonella foenum-graecum through in-vitro assays, and investigate its synergistic effects on glucose metabolism, lipid metabolism, and insulin function.Materials and methods: The polyherbal extract was prepared using methanol, water, and methanol-water as solvents. In-vitro antioxidant (DPPH, Phosphomolybdenum) and anti-diabetic (α-amylase, α-glucosidase inhibition, yeast glucose uptake, and inhibitory glucose diffusion) assays were conducted. L6 rat skeletal muscle cells were used for MTT assay and glucose uptake.Results: The methanol extract showed the highest antioxidant and anti-diabetic activities compared to aqueous and hydroalcoholic extracts. The IC50 values in DPPH and α-amylase inhibition assays were close to standard drugs, while the MTT assay demonstrated moderate cytotoxicity, confirming the extract's safety. Glucose uptake increased significantly, particularly in L6 cells treated with the methanolic extract.Conclusion: The polyherbal formulation exhibited potent anti-diabetic properties, particularly the methanolic extract, showing significant glucose regulation and insulin function improvement. This formulation holds promise as a natural treatment for diabetes.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2468128"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors of major lower limb amputation in symptomatic peripheral artery disease: a retrospective cohort study.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/20565623.2025.2476881

Supatcha Prasertcharoensuk, Krittin Prateepphuangrat, Phati Angkasith, Panu Teeratakulpisarn, Parichat Tanmit, Saowapa Chimluang, Kittisak Sawanyawisuth, Narongchai Wongkonkitsin

引用次数: 0

Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-04-01 DOI: 10.1080/20565623.2025.2458432

Zhaoyun Jiang, Bing Xu, Bo Sun, Beibei Yang, Su Lu, Mengjian Li, Juan Zhang, Liqiang Qi, Qixi Wu

{"title":"Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes.","authors":"Zhaoyun Jiang, Bing Xu, Bo Sun, Beibei Yang, Su Lu, Mengjian Li, Juan Zhang, Liqiang Qi, Qixi Wu","doi":"10.1080/20565623.2025.2458432","DOIUrl":"https://doi.org/10.1080/20565623.2025.2458432","url":null,"abstract":"Purpose: We aimed to identify the pathogenic variants of homologous recombination (HR) genes and analyze the correlation between the pathogenic variants and clinical characteristics in Chinese breast cancer patients.Methods: A cohort of 178 breast cancer patients participated in this study. We assessed genomic alterations using a 23-gene panel, which includes most of the HR-related genes and DNA mismatch repair (MMR) gene, through next-generation sequencing. The pathogenicity of variants was determined based on the American College of Medical Genetics and Genomics standards and guidelines. The correlation between these pathogenic variants and the clinical characteristics of the patients was investigated.Results: 26 pathogenic variants, including one novel suspected pathogenic variant, were detected in 28 (15.7%) patients. These variants occurred in 7 HR-related genes: BRCA1, BRCA2, PALB2, RAD51D, RAD50, BRIP1, and ATM. The frequency of BRCA1 variants was higher in the younger group (8.9%) compared to the older group (2.6%), while the trend was reversed for BRCA2 (3.0% vs. 7.8%). All three patients with the pathogenic variant (p.Lys91fs) in RAD51D were diagnosed with triple-negative breast cancer.Conclusions: HR-gene testing in breast cancer could help to find new suspected pathogenic variants and increase the clinical benefit of multi-gene testing for breast cancer.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458432"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the anoikis-cancer nexus: a bibliometric analysis of research trends and mechanisms.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-31 DOI: 10.1080/20565623.2025.2484159

Junjie Jiang, Wei Peng, Nianzhe Sun, Deze Zhao, Weifang Cui, Yuwei Lai, Chunfang Zhang, Chaojun Duan, Wei Zeng

{"title":"Unraveling the anoikis-cancer nexus: a bibliometric analysis of research trends and mechanisms.","authors":"Junjie Jiang, Wei Peng, Nianzhe Sun, Deze Zhao, Weifang Cui, Yuwei Lai, Chunfang Zhang, Chaojun Duan, Wei Zeng","doi":"10.1080/20565623.2025.2484159","DOIUrl":"10.1080/20565623.2025.2484159","url":null,"abstract":"Background: Cancer, influenced by genetics and the environment, involves anoikis, a cell death mechanism upon extracellular matrix detachment crucial for metastasis. Understanding this relationship is key for therapy. We analyze cancer and anoikis trends using bibliometrics.Methods: A search was conducted from Web of Science Core, PubMed, Scopus and non-English databases such as the CNKI (inception- 21 December 2024). Data analysis employed Microsoft Excel, VOSviewer, CiteSpace, R software, and the online platform (https://bibliometric.com/).Results: 2510 publications were retrieved, with a significant increase in the last decade. China led, the University of Texas system was productive, and the Oncogene Journal was popular. Breast, and colorectal cancers were frequently studied. Among them, representative tumor-related mechanisms were identified, commonalities such as (EMT, ECM, autophagy) and respective specific mechanisms were summarized.Conclusion: This bibliometric analysis highlights rapid advances in anoikis research in cancer, emphasizing EMT and FAK pathways' translational potential, guiding targeted therapies, and improving cancer treatment outcomes.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2484159"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

User-friendliness of the pain assessment in impaired cognition (PAIC15) in persons with aphasia: a pilot study.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/20565623.2025.2456440

Neeltje J de Vries, Hanneke J A Smaling, Jenny T van der Steen, Wilco P Achterberg

引用次数: 0

Colonic strictures in Crohn's disease: a non-surgical survival.

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-25 DOI: 10.1080/20565623.2025.2455911

Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker

{"title":"Colonic strictures in Crohn's disease: a non-surgical survival.","authors":"Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker","doi":"10.1080/20565623.2025.2455911","DOIUrl":"10.1080/20565623.2025.2455911","url":null,"abstract":"Background: Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.Patients and methods: A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis. Patients with uncertain diagnoses or follow-up periods of less than six months were excluded.Results: Fifty-six patients were included (median age 44 years [range 14-65], male-to-female ratio = 0.93). Surgery-free survival rates were 58.9% at 6 months, 43.7% at 2 years, and 31.7% at 5 years, with an average surgery-free survival of 46.7 months. Univariate analysis showed that joint manifestations (p = 0.01), corticosteroids (p = 0.02), anti-TNF alpha (p = 0.02), salicylates (p = 0.02), and azathioprine (p = 0.01) increased surgery-free survival. Complications such as collections or internal fistulas (p = 0.03), parietal ulceration on imaging (p = 0.01), and acute intestinal obstruction (p = 0.01) were associated with reduced surgery-free survival. In multivariate analysis, biologic therapy was the only independent protective factor against surgery (p = 0.001, OR = 0.19).Conclusion: The early introduction of biologic therapy is crucial for increasing surgery-free survival in patients with colonic stenosis in CD, given the limited effectiveness of conventional treatments.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2455911"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0